Michelle L. Basil Sells 12,990 Shares of Haemonetics Co. (NYSE:HAE) Stock

Haemonetics Co. (NYSE:HAEGet Free Report) EVP Michelle L. Basil sold 12,990 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $88.08, for a total transaction of $1,144,159.20. Following the sale, the executive vice president now owns 31,257 shares of the company’s stock, valued at $2,753,116.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Haemonetics Trading Down 1.7 %

Shares of HAE traded down $1.48 during midday trading on Wednesday, hitting $87.48. The stock had a trading volume of 944,572 shares, compared to its average volume of 497,897. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50. The stock’s 50 day moving average is $88.27 and its 200 day moving average is $83.44. The firm has a market cap of $4.45 billion, a PE ratio of 38.87, a price-to-earnings-growth ratio of 1.62 and a beta of 0.34.

Haemonetics (NYSE:HAEGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.02. The company had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. Haemonetics’s quarterly revenue was up 12.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 EPS. As a group, analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. Westfield Capital Management Co. LP grew its position in Haemonetics by 27.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after buying an additional 152,098 shares during the period. Vanguard Group Inc. increased its holdings in Haemonetics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after acquiring an additional 27,146 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Haemonetics during the 4th quarter worth about $888,000. Kingdon Capital Management L.L.C. acquired a new position in shares of Haemonetics during the 3rd quarter worth about $9,952,000. Finally, Lazard Asset Management LLC grew its stake in Haemonetics by 114.2% during the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 20,550 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HAE has been the subject of several research reports. TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Barrington Research upped their target price on shares of Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a report on Friday, May 10th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Needham & Company LLC restated a “hold” rating on shares of Haemonetics in a research note on Friday, May 10th. Finally, JMP Securities lifted their target price on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $108.67.

View Our Latest Research Report on HAE

Haemonetics Company Profile

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

See Also

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.